Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment
about
The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysisHBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data.HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patientsEfficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B.Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B InfectionClinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assayOn-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis BHepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analoguesHepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B.Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients.Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.Seroconversion of hepatitis B virus surface antigen in chronic hepatitis B child treated with entecavir.Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment.Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance.Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapyStability of hepatitis B surface antigen over time: Implications for studies using stored seraHBV therapeutic vaccines and cccDNA inhibitors - emergence of a cure
P2860
Q28533788-7C6F3854-EC65-46BE-866F-1C216713C22EQ30741676-2245FCD5-0FD8-433A-8BDA-09F0E987C3DAQ34505113-7354B654-4227-4595-99B7-2C5AD6DBA5DCQ35671645-4E3D7FE7-A871-4450-B520-730ED0866633Q36039553-A4FE9671-592A-4544-88CB-9DC8343D9E10Q36973383-C47A2ED9-CB15-47C6-A09F-0515FA5D53C1Q37135543-44B16250-338D-4844-9732-391C9EEDDE15Q37482902-37F9774C-DAB7-4F33-A2CB-D5A5BB1E7479Q38177851-A34A5AB1-5722-48E4-9C61-CD7D18CECF5FQ38224440-D1CE4F4D-ADEE-4BD6-B349-8CB217473398Q40272794-F948EA3C-9563-4857-966F-90A56B26ED49Q40324314-283A77DF-E6D6-4C68-AC3A-593913A51CA9Q41121379-CF7CF78D-1552-4260-A9AC-7824DB80E931Q41719578-0D8182AE-4F51-4B8C-A6B8-9A0AFB35FE2EQ41791106-4976E28F-DEB1-48F3-98E8-455E638B0AF4Q41879601-7AE02F8E-6B40-408A-AD74-1E27B828B280Q42199429-05F18344-25E2-425E-9E75-747D3B5B6DD7Q42217913-9115955D-2AB1-4B14-9514-E9E292CFE5ECQ42223321-60931C49-BA67-464B-ABFB-B53742DD3ED2Q42249938-E959D2BA-07B6-4750-853C-4297C039058AQ42263556-94D63881-5084-4ACF-A34A-D75E236DD508Q44766209-73D45A0D-831F-4988-A31E-1901014D8415Q45350931-11D50E10-1128-4552-8DFA-513505A385A3Q58235736-DEC4D495-DE8D-4EF5-A161-B16F971D23A2Q58235845-2DB7E0F4-6F09-4BC3-AEFC-07A55FFA9D2CQ58376390-0A65D902-C81C-4F07-A534-C4EF7080C09C
P2860
Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment
description
article
@en
im August 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2011
@uk
name
Quantitative Hepatitis B Surfa ...... 2 Years of Entecavir Treatment
@en
Quantitative Hepatitis B Surfa ...... 2 Years of Entecavir Treatment
@nl
type
label
Quantitative Hepatitis B Surfa ...... 2 Years of Entecavir Treatment
@en
Quantitative Hepatitis B Surfa ...... 2 Years of Entecavir Treatment
@nl
prefLabel
Quantitative Hepatitis B Surfa ...... 2 Years of Entecavir Treatment
@en
Quantitative Hepatitis B Surfa ...... 2 Years of Entecavir Treatment
@nl
P2093
P2860
P50
P356
P1476
Quantitative hepatitis B surfa ...... 2 years of entecavir treatment
@en
P2093
Danny Ka-Ho Wong
John Young
Man-Fung Yuen
P2860
P304
P356
10.1038/AJG.2011.253
P407
P577
2011-08-09T00:00:00Z